Phospho-EGFR (Tyr1068) Polyclonal Antibody | Invitrogen 44-788G product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Phospho-EGFR (Tyr1068) Polyclonal Antibody

catalog :

44-788G

quantity :

100 µL

price :

US 514

clonality :

polyclonal

host :

domestic rabbit

conjugate :

nonconjugated

antigen modification :

phosphorylated

reactivity :

human, rat

application :

western blot, immunocytochemistry

more info or order :

Invitrogen product webpage

citations: 25

Published Application/Species/Sample/Dilution	Reference
western blot; human; loading ...; fig e11-7b	Wang C, Vegna S, Jin H, Benedict B, Lieftink C, Ramirez C, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature. 2019;: pubmed publisher
western blot; human; 1:2000; loading ...; fig 3	Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, et al. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol. 2017;143:573-600 pubmed publisher
western blot; human; fig 1	Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam K, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE. 2016;11:e0147344 pubmed publisher
	Sidorov M, Dighe P, Woo R, Rodriguez Brotons A, Chen M, Ice R, et al. Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment. Cells. 2023;12: pubmed publisher
	Dieter S, Lovecchio D, Pataskar A, Zowada M, K xf6 rner P, Khalizieva A, et al. Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Oncogene. 2022;41:3953-3968 pubmed publisher
	Moritz S, Krause M, Schlatter J, Cordes N, Vehlow A. Lamellipodin-RICTOR Signaling Mediates Glioblastoma Cell Invasion and Radiosensitivity Downstream of EGFR. Cancers (Basel). 2021;13: pubmed publisher
	Fu C, Zhang Q, Wang A, Yang S, Jiang Y, Bai L, et al. EWI-2 controls nucleocytoplasmic shuttling of EGFR signaling molecules and miRNA sorting in exosomes to inhibit prostate cancer cell metastasis. Mol Oncol. 2021;15:1543-1565 pubmed publisher
	Jang E, Sung J, Yoo H, Jang H, Shim J, Oh E, et al. FAM188B Downregulation Sensitizes Lung Cancer Cells to Anoikis via EGFR Downregulation and Inhibits Tumor Metastasis In Vivo. Cancers (Basel). 2021;13: pubmed publisher
	Han S, Kim K. RNF144a induces ERK-dependent cell death under oxidative stress via downregulation of vaccinia-related kinase 3. J Cell Sci. 2020;133: pubmed publisher
	Raim xfa ndez E, Keller S, Zwingenberger G, Ebert K, Hug S, Theis F, et al. Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell lines. PLoS Comput Biol. 2020;16:e1007147 pubmed publisher
	Manabe T, Yasuda H, Terai H, Kagiwada H, Hamamoto J, Ebisudani T, et al. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Mol Cancer Res. 2020;18:549-559 pubmed publisher
	Armistead J, Hatzold J, van Roye A, Fahle E, Hammerschmidt M. Entosis and apical cell extrusion constitute a tumor-suppressive mechanism downstream of Matriptase. J Cell Biol. 2020;219: pubmed publisher
	Ebert K, Mattes J, Kunzke T, Zwingenberger G, Luber B. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells. PLoS ONE. 2019;14:e0223225 pubmed publisher
	Mumin N, Drobnitzky N, Patel A, Lourenco L, Cahill F, Jiang Y, et al. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer. BMC Cancer. 2019;19:102 pubmed publisher
	Yan X, Shen H, Jiang H, Hu D, Wang J, Wu X. YXQ-EQ Induces Apoptosis and Inhibits Signaling Pathways Important for Metastasis in Non-Small Cell Lung Carcinoma Cells. Cell Physiol Biochem. 2018;49:911-919 pubmed publisher
	Floc h N, Martin M, Riess J, Orme J, Staniszewska A, Ménard L, et al. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther. 2018;17:885-896 pubmed publisher
	Keller S, Zwingenberger G, Ebert K, Hasenauer J, Wasmuth J, Maier D, et al. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. Mol Oncol. 2018;12:441-462 pubmed publisher
	Masuzawa K, Yasuda H, Hamamoto J, Nukaga S, Hirano T, Kawada I, et al. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. Oncotarget. 2017;8:105479-105491 pubmed publisher
	Keller S, Kneissl J, Grabher Meier V, Heindl S, Hasenauer J, Maier D, et al. Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis. BMC Cancer. 2017;17:845 pubmed publisher
	Ren Y, Zheng J, Fan S, Wang L, Cheng M, Shi D, et al. Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification. Oncotarget. 2017;8:50832-50844 pubmed publisher
	Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, et al. Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2017;77:2078-2089 pubmed publisher
	Tani T, Yasuda H, Hamamoto J, Kuroda A, Arai D, Ishioka K, et al. Activation of EGFR Bypass Signaling by TGFÎ± Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. Mol Cancer Ther. 2016;15:162-71 pubmed publisher
	Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, et al. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 2015;6:38789-803 pubmed publisher
	Holland W, Chinn D, Lara P, Gandara D, Mack P. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 2015;141:615-26 pubmed publisher
	Obama T, Takayanagi T, Kobayashi T, Bourne A, Elliott K, Charbonneau M, et al. Vascular induction of a disintegrin and metalloprotease 17 by angiotensin II through hypoxia inducible factor 1?. Am J Hypertens. 2015;28:10-4 pubmed publisher

product information

Product Type :

Antibody

Product Name :

Phospho-EGFR (Tyr1068) Polyclonal Antibody

Catalog # :

44-788G

Quantity :

100 µL

Price :

US 514

Clonality :

Polyclonal

Purity :

Antigen affinity chromatography

Host :

Rabbit

Reactivity :

Human, Rat

Applications :

Immunocytochemistry: 1:100, Western Blot: 1:1,000

Species :

Human, Rat

Isotype :

IgG

Storage :

-20°C

Description :

EGFR, epidermal growth factor receptor, is a receptor tyrosine kinases that signals in response to various growth factors. Overexpression has been linked to numerous types of cancer and EGFR is the target of both biological and small molecular therapeutics. EGFR is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Immunogen :

The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human EGFR that contains tyrosine 1068. The sequence is conserved in rat.

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:100, Western Blot: 1:1,000

Aliases :

2.7.10.1; 9030024J15Rik; AI552599; avian erythroblastic leukemia viral (v-erbB) oncogene homolog; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; EC 2.7.10.1; egf receptor; Egfr; EGFR-related peptide; epidermal growth factor receptor; epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian); Epidermal growth factor receptor formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); epidermal growth factor receptor, formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); ERBB; ERBB1; ErbB-1; erb-b2 receptor tyrosine kinase 1; Errb1; Errp; HER1; kinase EGFR; mENA; NISBD2; Oncogene ERBB; PIG61; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; Urogastrone; wa2; wa-2; Wa5; waved 2

more info or order :

Invitrogen product webpage